Plné znění - 2/2008 Sb. m. s.

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx sděluje, že xxx 16. xxxxxxxxx 2007 xxxx generálním xxxxxxxxx XXXXXX, xxxxxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx¹⁾, xxxxxxxx xxxxxxxxx xxxxxx xxxxx Přílohy I - Xxxxxxx xxxxxxxxxx xxxxx x metod xxxxxxx.

Xxxxxxx I xxxxxxxxx x xxxxxxxx v xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2008 a tímto xxxx xxxxxxxxx x xxxxxxxx x pro Xxxxxx xxxxxxxxx. Dnem xxxxxx Přílohy I x xxxxxxxx přestává xxxxxx Příloha X Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xx znění xxx xxx 2007, vyhlášená xxx č. 59/2007 Xx. x. s.

Xxxxxxxx xxxxx Xxxxxxx X x její xxxxxxx do xxxxxxx xxxxxx se vyhlašují xxxxxxxx.

X1. ANABOLICKÉ XXXXX

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):

x. Exogenní * XXX, zahrnující:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-androstendion (5α-androst-1-en-3,17-dion); xxxxxxxxx (19-xxxxxxxxxxxxxxxx); bolasteron; xxxxxxxx; xxxxxxx (androsta-1,4-dien-3,17-dion); xxxxxxx (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazol); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-nor-17α-pregn-4-en-17-ol); xxxxxxxxxxxxxx; xxxxxxxxxx; furazabol (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; mesterolon; metandienon (17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; methandriol; xxxxxxxxxx (2α, 17α-xxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9,11-xxxxx-3-xx); methyltestosteron; xxxxxxxxx; nandrolon; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; oxabolon; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx ([3,2-x]xxxxxxx-5α-xxxxxxxxxxxxxx-17β-xxxxxxxxxxxxxxxxx); quinbolon; xxxxxxxxxx; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.

x. Xxxxxxxxx ** XXX:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), testosteron x xxxxxxxxxxx metabolity x xxxxxxx:

5α-androstan-3α,17α-diol androst-5-en-3β,17α-diol

5α-xxxxxxxxx-3α,17β-xxxx 4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)

5α-xxxxxxxxx-3β,17α-xxxx 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)

5α-xxxxxxxxx-3β,17β-xxxx xxx-xxxxxxxxxxxxxxxxxx

xxxxxxx-4-xx-3α,17α-xxxx 3α-xxxxxxx-5αxxxxxxxxx-17-xx

xxxxxxx-4-xx-3α,17β-xxxx 3β-xxxxxxx-5αxxxxxxxxx-17-xx

xxxxxxx-5-xx-3β,17α-xxxx 19-xxxxxxxxxxxxxx

xxxxxxx-5-xx-3α,17α-xxxx 19-xxxxxxxxxxxxxxxxx

xxxxxxx-5-xx-3α,17β-xxxx

X xxxxxxxxx, xxx může xxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxx přirozeně, xxxx se xxx xx xx, xx Xxxxxx xxxxxxxx tuto Xxxxxxxxx látku a xxxx xxxxxx pozitivní Xxxxxxxxx xxxxxxxxxxx nález, xxxx xx xxxxxxxxxxx Xxxxxxxx látky xxxx xxxxxx metabolitů xxxx xxxxxxxxxxx x/xxxx když xx xxxxxxxx xxxx xxxxxxxxx xxxxx ve Xxxxxx Xxxxxxxxx xxxxxxxx xxxxxxxxx xx xxxxxxx xxxxxx, xxxxx se xxxxxxxx xxxxxxxxx x xxxx tak, xx xxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx. Xxxxxx xx xxx xx xx, xx Vzorek obsahuje Xxxxxxxxx látku v xxxxxxx xxxxxxx, xxxxx Xxxxxxxxx xxxxxxx, že xx koncentrace Xxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxx nebo xxxxxxxxxx x/xxxx xxxxxxxxx poměr xx Xxxxxx Xxxxxxxxx xxxxxxxx xxxxxxxxxxxxx nebo xxxxxxxxxxxx xxxxxx.

Bude xx xxx xx xx, že Vzorek Xxxxxxxxx xxxxxxxx Zakázanou xxxxx x xxxxxxxxx xxxxxxx Xxxxxxxxx laboratorní xxxxx xx všech xxxxxxxxx x xxx xxxxxxxxx xxxxxxxxxxx, xxxxx xxx xxxxx spolehlivé xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxx, že xx Xxxxxxxx xxxxx xxxxxxxxxx xxxxxx. X xxxxxxx xxxxxxx není xxxxx provádět další xxxxxxx.

Když xx xxxxxxx výsledku xxxxxxx xxxxxxxx xxxxxxxxxxx xx xxxxxxx xxxxxx, xxxxx xx xxxxxxxx vyskytují x lidí x xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxxxxx exogenní původ Xxxxxxxx látky, ale xxxxxxxx známky xxxxxxx Xxxxxxxx látky, xxxx xxxx. porovnání s xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, nebo když xxxxxxxxx xxxxxxxxx poměr X/X xxxxx než xxxxx (4) ku xxxxx (1) x xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx xxxxx, xxxxxxx xxxxxxxxx Xxxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx nebo xxxxxxxxxx xxxxxxxxxx xxxxx.

Xx-xx xxxxxxxxxx xxxxxx xxxxx xxxxxxx, pak xxxxxxxx bude laboratoří xxxxxx xxxx xxxxxxxxx x xx xxxx xxxxxxxxx. Pokud laboratoř xxxxxxx, za xxxxxxx xxxxxxxxxx analytické xxxxxx (xxxx. XXXX) xxxxxxxx xxxxx Zakázané xxxxx, xxxx xxxxx provádět xxxxx xxxxxxx, a xxxx xx mít xx xx, xx Xxxxxx xxxxxxxx Zakázanou xxxxx. Xxxxx xxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) x xxxxxx x xxxxxxxxx minimálně 3 xxxxxxxxx xxxxx, xxxx xxxxxxx longitudinální xxxxxx Xxxxxxxxx tím, že xxxx příslušnou Xxxxxxxxxxxxxx xxxxxxxxxx x xxxxxxxxxxxxx 3 měsících třikrát xxxxxxxx bez xxxxxxxxxxx xxxxxxxx. Xxxxxxxx, který xxxxxxxxxx tuto xxxxxxxxxxxxxx xxxxxx, xxxx hlášen xxxx xxxxxxxxx. Xxxxx xxxxxxxxxxxxxx xxxxxx Xxxxxxxxx, xxxxxxxx xxxxxxxxxx xxxxx, xxxx xxxxxxxxxxxx normální, xxxx xx xxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx.

V xxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx může xxx x moči trvale xxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx ve velice xxxxxx koncentracích (xx/xx). Xxxxx xxxxxxxxx xxxxxx xxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxxxxx exogenní xxxxx Xxxxxxxx látky, xxxx xxx xxxxxxxxx xxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx (následných testů).

Xxxxx laboratoř xxxxxxxxx Xxxxxxxxx laboratorní xxxxx 19-xxxxxxxxxxxxxxx, xxxx xx xx považovat za xxxxxxx x xxxxxxxxxxx xxxxx exogenního xxxxxx Xxxxxxxx xxxxx. V xxxxxxx případě xxxx xxxxx xxxxxxxx další xxxxxxx.

X případě, xx Xxxxxxxxx xxxxxx xxxxxxxxxxxxx xxx xxxxxxx xxxxxxxxx, bude se xxx xx to, xx Xxxxxx Xxxxxxxxx xxxxxxxx Zakázanou xxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SARM), xxxxxxx, xxxxxxx, xxxxxxxxxx, ale xx s omezením xxxxx na xx.

X2. XXXXXXX X PŘÍBUZNÉ XXXXX

Následující xxxxx x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxxxx (XXX);

2. Růstový xxxxxx (xXX), xxxxxxxx podobné xxxxxxx faktory (např. XXX-1), mechanické xxxxxxx xxxxxxx (XXX);

3. Xxxxxxxxxxxxx (např. LH, xXX), xxxxxxxx xxx x xxxx;

4. Xxxxxxxx;

5. Xxxxxxxxxxxxxx

x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxx Xxxxxxxxx xxxxxx prokázat, xx xxxxxxxxxxx byla xxxxxxxxx xxxxxxxxxxxxx či xxxxxxxxxxxx xxxxxx, bude xx xxx xx xx, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx (xxx je uvedeno xxxx) x případech, xxx xxxxxxxxxxx Zakázané xxxxx xxxx xxxxxx xxxxxxxxxx či xxxxxxxxxx x/xxxx xxxxxxxxx xxxxxx xx Vzorku Xxxxxxxxx xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx zjištěné u xxxx xxx, xx xxxxxxxxxxxx normální endogenní xxxxxxxx.

Xxxxx xxxxxxxxx xxxxxxxxx, xx xxxxx xxxxxxxxxx xxxxxxxxxx metody, xx Zakázaná xxxxx xx xxxxxxxxxx původu, xxxx se mít xx xx, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx a xxxx xxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx.

X3. XXXX-2 XXXXXXXX

Všichni xxxx-2 xxxxxxxx xxxxxx xxxxxx X- x X-xxxxxxx xxxx zakázáni.

Xxxxxxxx xxxx xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx a xxxxxxxxxx, pro xxxxx xx xxx inhalaci xxxxx xxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxx.

I xxxx xxxx xxxxxxx xxxxxxxx xxxxx terapeutické xxxxxxx, xxxx xxxxx xxxxxxxxxxx (volný plus xxxxxxxxxx) xxxxx xxx 1000 xxxxxxxxx x 1 mililitru xxxx xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx Xxxxxxxxx neprokáže, že xxxxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxxxxxxxx užíváním xxxxxxxxxxx x xxxxxxxx.

X4. XXXXXXXXXXX X XXXXXXXXXX HORMONŮ

Xxxxxxxxxxx xxxxxxx jsou xxxxxxxx:

1. Xxxxxxxxxx xxxxxxxx, zahrnující:

2. Xxxxxxxxxx modulátory xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxx:

3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:

4. Xxxxx xxxxxxxxxxxx funkce xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.

X5. XXXXXXXXX A XXXXXXX XXXXXXXXX XXXXX

Maskovací xxxxx xxxx xxxxxxxx. Xxxxxxxx:

Xxxxxxxxx*, xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx xxxx-xxxxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxx), xxxxxxxxxxxxxxx (xxxx. xxxxxxx, xxxxxxx, xxxxxxxxxxxxxxxxx) x další xxxxx x xxxxxxxxx xxxxxxxxxxxx účinky.

Diuretika xxxxxxxx:

Xxxxxxxxxxxx, amilorid, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, kyselina xxxxxxxxxx, metolazon, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, chlorothiazid), xxxxxxxxxx x xxxxx látky x podobnou xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxx není xxxxxxxx).

* Terapeutická xxxxxxx xxxx xxxxxx, xxxxx xxx Xxxxxxxxx xxxxxxxx xxxxxxxxx ve xxxxxxx x xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxx Xxxxxxxx xxxxx (xxxxx).

X1. ZVYŠOVÁNÍ XXXXXXX XXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX

X3. XXXXXX DOPING

Xxxxxxxxxxxxxx xxxxxxx xxxxx, xxxx, xxxxxxxx xxxxxxxx, xxxx xxxxxxxxxx xxxxxxx genů, xxxxx mají xxxxxxxxx xxxxxx xxxxxxxxx xxxxx, xx xxxxxxxx.

X6. STIMULANCIA

Xxxxxxx xxxxxxxxxxx (včetně xxxx xxxxxx případných xxxxxxxxx (X- x X-) xxxxxxx) xxxx zakázaná, x xxxxxxxx derivátů xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx užití x stimulancií xxxxxxxxxx xx Xxxxxxxxxxxxxx programu xxx xxx 2008.

Xxxxxxxxxxx xxxxxxxx:

Xxxxxxxxx, xxxxxxxxx**, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, bromantan, cyklazodon, xxxxxxxxxxxxxxxxx, xxxxxxx****, xxxxxxxx, xxxxxxxxx, ethylamfetamin, famprofazon, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, fenkamfamin, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (karfedon), xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxx***, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, levmetamfetamin, xxxxxxxxx, mefentermin, meklofenoxát, xxxxxxxxxxxx (D-), metylefedrin****, xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx, modafinil, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, parahydroxyamfetamin, xxxxxxx, xxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, selegilin, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxxxxxx neuvedené xxxxxxxx xxxx příklady x xxxxx oddíle xxxx xxxxxxxxxx xx specifickou xxxxx pouze, xxxxx Xxxxxxxxx xxxxxxx, xx xxxx xxxxxxxxx xxxxxxxxxx x xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx, xxxx xx x xxx menší xxxxxxxxxxxxxxx, xx xxxx xxxxxxx xxxxxxxx jako dopingová xxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx narkotika xxxx xxxxxxxx:

Buprenorfin, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), fentanyl x xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, morfin, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.

S8. XXXXXXXXXXX

Xxxxxxxxxxx (např. xxxxx, xxxxxxxxx) jsou xxxxxxxx.

S9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx glukokortikosteroidy xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx. Xxxxxx užití xxxxxxxx xxxxxxxxxxxxx xxxxxxx.

Jiné xxxxxxx injekční xxxxxxxx (xxxxxxxxxxxx, do xxxxx xxxxxx, xx xxxxx xxxxxx, xxxxxxxxxx, do xxxx) a xxxxxxxxx xxxxxxxx xxxxxxxx zkrácenou xxxxxxxxxxxxx výjimku s xxxxxxxx níže uvedených.

Xxxxxxx xxxxxxxxx podávané xx xxxxxx kožní (xxxxxx iontoforézy/fonoforézy), xxxx, xxxxx, xxxx, xxxxxx xxxxx řitního otvoru, xxxxxxxx úst x xxxxx xxxxxx zakázané x xxxxxxxxxx xxxxxx xxxxx xxxxxxxxxxxx xxxxxxx.

P1. XXXXXXX

Xxxxxxx (etanol) xx xxxxxxxx pouze Xxx xxxxxxx v xxxxxxxxxxxxx sportech. Xxxxxxx xx bude provádět xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxx. Prahová xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx pro xxxxxx federaci uvedena x závorkách.

∙ Xxxxxxxxxxxx xxxxx (XXX) (0.10 x/x)

∙ Xxxxxx (XXX) (0.10 x/x)

∙ Xxxxxxx xxxxxx a parašutismus (XXX) (0.20 x/x)

∙ Lukostřelba (XXXX, XXX) (0.10 x/x)

∙ Xxxxxxx xxxxxxx (XXXX) xxx xxx xxxxxxxxxx se xxxxxxxx (0.10 x/x)

∙ Xxxxxxxxxxx xxxxx (XXX) (0.10 g/l)

∙ Xxxxx xxxxxxxxxx (XXX) (0.30 g/l)

∙ Kuželky (XXX) (0.10 x/x)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx Xxx xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.

∙ Automobilový sport (XXX)

∙ Xxxxxxxx (XXXX)

∙ Xxxx (XXXX)

∙ Xxxxx (XXX)

∙ Curling (XXX)

∙ Xxxxxxxxxx (XXX)

∙ Xxxxxxxx (XXXX) - "xxxxx xxxx" - xxx xxxxxxxxxxx

∙ Xxxxxxx (XXX)

∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)

∙ Xxxxxxxxxxx (XXXX, IPC) (zakázané xxxx Xxxx soutěž)

∙ Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx, x snowboard X-xxxxx x "xxx xxx"

∙ Xxxxxxx xxxxxxx (XXXX) - jen xxxxxxxxxx xx xxxxxxxx

∙ Xxxxxxxxxxx sport (XXX)

∙ Xxxxxxxx x obdobné xxxxxx (XXXX, XXX "bowls")

∙ Střelba (XXXX, XXX) (xxxxxxxx také Xxxx xxxxxx)

∙ Xxxxx xxxxxxxxxx (XXX)

∙ Xxxxx (XXXX)

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Acebutolol, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx

"Specifické xxxxx"* xxxx xxxxxxxxxxx xxxx:

∙ Všichni Xxxx-2 xxxxxxxx x xxxxxxxx, xxxxx xxxxxxxxxxx (volného xxxx xxxxxxxxxxx) xxx xxxxxxxx větším xxx 1000 xx/xx moči x xxxxxxxxxxxx (xxxxxxx xx skupině S 1.2 Xxxxxxx xxxxxxxxxx xxxxx);

∙ Xxxxxxxxxx xxxx-xxxxxxxxx, probenecid;

∙ Xxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, meklofenoxát, x-xxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, ortetamin, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, sibutramin, xxxxxxxxxxxxx x xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx v xxxxxx X6, xxx která Xxxxxxxxx xxxxxxx, xx xxxxxxx podmínky xxxxxxx x xxxxxx X6;

∙ Xxxxxxxxxxx;

∙ Xxxxxxx Glukokortikosteroidy;

∙ Xxxxxxx;

∙ Xxxxxxx Xxxx-xxxxxxxxx.

*"V Xxxxxxx xxxxx být xxxxxxxxxxx xxxxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx pravidel, xxxxxxx xxxx xxxxxxxxx xxxxxxxx x xxxxxxx xxxxxxxxx xxxxxxxxxxx, xxxx x xxxxx xx xxxxx pravděpodobnost, že xxxxx xxxxxxx xxxxxxxx xxxx xxxxxxxxx xxxxxxx." Xxxxxxxx xxxxxxxxxxxxxxx pravidla xxxxxxxxxx xxxxxxxx xxxxx xxxx xxxxxxxx xxxxxxx xxxxxx xx předpokladu, xx "...Xxxxxxxxx xxxx xxxxx prokázat, xx Xxxxxxx xxxxxxxxxx xxxxx xxxxxx zamýšleno xx xxxxxxx xxxxxxxxxxx výkonu...".

Xxxxxx xxxxxxx x. 2/2008 Sb. x. x. nabyl xxxxxxxxx xxxx 31.1.2008.

Xxxxxx xxxxxxx x. 2/2008 Xx. x. x. xxx zrušen xxxxxxx předpisem č. 8/2009 Sb. m. s. x účinností xx 7.2.2009.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x odkazech xxxx xxxxxxxxxxxxx, xxxxx se xxxx netýká xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu.